Table 2 Estimated age-specific QoL-AGHDA score at baseline, first-year treatment effect, and drug utilisation

12+

18–30

16.37

−7.05^a

14.60

−5.48

0.30

0.22

31–54

16.25

−6.53

16.57

−5.48

0.26

0.36

55–65

16.06

−9.40

17.13

−4.25

0.23

0.29

65+

16.80

−9.25

14.20

−2.00

0.39

0.25

7–11

18–30

8.92

−3.43

8.67

−2.33

0.24

0.25

31–54

8.37

−3.43

8.64

−2.65

0.23

0.33

55–65

9.25

−4.75

8.21

−2.44

0.23

0.28

65+

9.15

−3.54

9.17

−4.42

0.25

0.21

2–6

18–30

3.20

1.00

4.00

0

0.54

0.18

31–54

3.85

−1.10

4.17

−1.81

0.30

0.44

55–65

4.07

−1.71

3.92

−1.60

0.28

0.25

65+

4.2

0

4.14

−1.67

0.24

0.25

<2

18–30

0.50

3.00

1.00

−1.00

0.41

0.26

31–54

0.22

0.60

0.40

0

0.34

0.43

55–65

0.40

0.81

0.14

0

0.28

0.30

65+

0.08

1.44

0.67

0.5

0.18

0.23